Understanding Rising Pharmacy Costs: Insights from SHARx on Effective Budget Management

The Pharmacy Budget Trap: Insights from SHARx

In a recent discussion led by Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx, it was emphasized that merely relying on discounts and rebates does not adequately control pharmacy spending. As the demand for GLP-1 medications, specialty drugs, and high-cost therapies continues to grow, employers must adopt a more holistic approach to managing their pharmacy budgets.

The Illusion of Savings

Pruitt pointed out that a larger rebate may create a misleading sense of financial relief. He noted the critical distinction: “A bigger discount on an escalating drug price can create the illusion of savings.” This statement underscores a significant concern among employers who often assess pharmacy performance based solely on the discounts they receive, neglecting to consider how utilization rates and expanding patient populations influence overall costs. As prescription volumes increase, it is possible to secure better rebates while overall spending continues to rise.

For instance, consider a hypothetical plan covering 100 members where each member requires a therapy costing $10,000 annually. Initially, this totals $1 million. If a 10% reduction in price is secured, yet the number of users grows to 140, the total expenditure would skyrocket to approximately $1.26 million, demonstrating a 26% increase despite the apparent unit price discount. This scenario exemplifies the unintended consequences of focusing on unit price without regard for demand.

Forecasting Pharmacy Costs

To combat rising costs, Pruitt advocates for forecasting pharmacy expenses proactively. Employers should monitor trends related to high-cost therapies such as GLP-1s, oncology treatments, and gene therapies, and not just historical claims. It is crucial to track metrics such as the rate at which new members start these therapies and their treatment persistence across different medication categories.

For example, SHARx identified changing utilization patterns within six months for a group of 500 members before these patterns impacted its budget significantly. Pruitt remarked, “What appeared to be a stable pharmacy plan became a significant increase in spending.” By implementing regular reviews, employers can adapt their sourcing strategies and budgetary plans well ahead of contract renewals.

Sustainable Access Over Restrictions

Pruitt also addressed the balance between cost control and medication access. He cautioned against sweeping restrictions that might delay necessary treatments and lead to employee dissatisfaction. “The objective is sustainable access, not indiscriminate approval or denial,” he stated. Employers should aim for a responsible approach that combines effective clinical guidelines with patient advocacy initiatives to ensure that members receive the necessary support and medications without losing access to required therapies.

To illustrate this point, a SHARx member shared a personal story about being denied coverage for a critical medication. The member stated, “Without coverage, this medication would cost me $10,000 every month. SHARx has been a literal lifesaver by providing my medication at no cost to me.” Such testimonials highlight the importance of continued access alongside effective budgeting strategies.

Prioritizing Pharmacy as a Risk-Management Area

Leaders in human resources and finance must recognize the implications of increased demands for high-cost therapies and their effect on total spending. Pharmacy should be viewed as a critical area for risk management rather than an isolated budget line.

Pruitt concluded, “A forecast is only valuable if it provides employers a clear vision of their expenses and helps them alter outcomes.” Simply restricting access to medications to control costs is not a sustainable solution, as this merely shifts the financial burden without addressing the root problems of rising healthcare costs.

About SHARx

SHARx emerged from a desire to disrupt the overpriced prescription drug paradigm. Founded by industry veterans Corey Durbin and Paul Pruitt, the organization is committed to prioritizing patient needs over profits. With its unique sourcing model that emphasizes transparency and ethical practices, SHARx strives to provide affordable access to essential medications while eliminating hidden costs and complexities.

For further insights on pharmacy benefits management and effective cost control strategies, visit SHARXplan.com.